By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Enteris Biopharma 

83 Fulton Street

Boonton  New Jersey  07005  U.S.A.
Phone: 973-453-3530 Fax: 973-585-1229


Drug Delivery

Company News
Enteris Biopharma Doses First Woman In Phase IIa Clinical Trial Of Ovarest (Oral Leuprolide Tablet) For Endometriosis 8/24/2017 7:51:05 AM
Ferring Pharma And Enteris Biopharma Enter License Agreement To Develop An Oral Formulation Of A Peptide-Based Injectable Therapeutic 1/30/2017 6:42:43 AM
Enteris Biopharma Release: Company Enters Into Agreement With Nordic Bioscience A/S's KeyBioscience To Develop Orally Delivered Metabolic Peptide 1/25/2017 7:21:01 AM
Enteris Biopharma Release: Company Enters Agreement With Sanofi (SNY) To Develop Investigational Oral Therapeutic For Type 2 Diabetes 1/23/2017 9:14:13 AM
Enteris Biopharma's "Feasibility To Licensing" Partner, Cara Therapeutics (CARA), Advances Peptelligence-Engineered CR845 Into Phase 2b Clinical Trial In Chronic Pain 9/19/2016 7:29:27 AM
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016 6:19:57 AM
Enteris Biopharma Enhances Executive Leadership Team To Target Strategic Growth Opportunities 1/19/2016 6:51:20 AM
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Tarsa Therapeutics' TBRIA - The First Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis 10/19/2015 12:50:19 PM
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide In Phase 2 Trial In Osteoarthritis 8/20/2015 8:33:52 AM
Enteris Biopharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics, Inc. (CARA)' CR845 7/14/2015 11:21:12 AM